Lobinaline N-Oxides for Dual DAT and nicAChR Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for substance use disorders, particularly alcohol and nicotine use disorders, are inadequate, and there is a need for more effective pharmacotherapies that can address both disorders simultaneously.
Innovation Solution
Development of lobinaline N-oxides, which are novel compounds derived from Lobelia cardinalis through target-directed evolution, that modulate both the dopamine transporter and nicotinic acetylcholine receptors, offering a dual mechanism of action to reduce the reinforcing effects of substances of abuse.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional DAT inhibitors are developed, then dopamine transporter inhibition is achieved, but abuse liability increases
Solution Approach 1:
The invention changes the chemical parameters of DAT inhibitors by developing atypical inhibitors with distinct molecular structures and binding mechanisms. These atypical DAT inhibitors exhibit different pharmacological profiles that maintain therapeutic efficacy while reducing abuse liability through modified interaction patterns with the dopamine transporter.
Solution Approach 2:
The invention applies local quality by targeting specific functional characteristics of the DAT protein through atypical binding modes. The atypical inhibitors interact with distinct regions or conformational states of the DAT, achieving selective modulation that preserves therapeutic action while minimizing reinforcing effects associated with classic inhibition patterns.
2Object-affected harmful factors
If nicAChR function is inhibited, then positive reinforcement for nicotine use is reduced, but withdrawal substitution capability is lost
Solution Approach 1:
The invention applies partial action by developing partial agonists at nicAChRs that produce sub-maximal activation compared to full agonists like nicotine. This partial activation is sufficient to reduce positive reinforcement and provide withdrawal substitution, while avoiding the excessive stimulation that would precipitate withdrawal or produce strong reinforcing effects.
Solution Approach 2:
The invention changes the functional parameter of nicAChR activation from full agonism to partial agonism. This parameter change in receptor activation level allows the compound to occupy and partially activate receptors, providing therapeutic benefit through reduced reinforcement and withdrawal substitution without the harmful effects of full agonist activity.
3Reliability
If single-target therapies are used, then specific disorder treatment is effective, but co-occurring disorders are not addressed
Solution Approach 1:
The invention applies universality by developing compounds with multiple pharmacological activities that can treat different substance use disorders. The atypical DAT inhibitors and nicAChR partial agonists exhibit dual or multi-target functionality, allowing a single agent to address both nicotine and alcohol use disorders through its combined effects on these neurotransmitter systems.
Solution Approach 2:
The invention merges multiple therapeutic mechanisms into single compounds or combination regimens. By combining DAT inhibition with nicAChR partial agonism in one pharmacological profile, the invention creates a unified treatment approach that simultaneously addresses multiple disorder mechanisms, improving versatility for co-occurring disorders.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Lobinaline N-oxides demonstrate potent inhibitory effects on the dopamine transporter and partial agonist activity on nicotinic acetylcholine receptors, potentially providing a more effective treatment for substance use disorders by reducing the positive reinforcement of alcohol and nicotine use without causing withdrawal symptoms.
Implementation Method 1
Lobinaline N-oxides as positive allosteric modulators of the dopamine transporter
Implementation Method 2
partial agonist activity on nicotinic acetylcholine receptors
Data Source
AI summary
The presently-disclosed subject matter describes Lobinaline N-oxides as modulators of the dopamine transporter. The presently-disclosed subject matter further describes to Lobinaline N-oxides as modulators of the nicotinic acetylcholine receptors. Also described herein are methods for treating substance abuse disorders comprising administering Lobinaline N-oxides to a subject in need thereof.